Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy.
R Niehues(Zentrum für Kinderheilkunde), Thorsten Marquardt(Klinik und Poliklinik für Kinder- und Jugendmedizin), Karl Reiter(University of Vienna), E. Harms(Zentrum für Kinderheilkunde), Martin Hasilik(Zentrum für Kinderheilkunde), Hans‐Georg Koch(University of Freiburg), Christian Körner(University of Basel), M Schiebe-Sukumar(Zentrum für Kinderheilkunde), Gordon Alton(Pfizer (United States)), Rongrong Wu(Guangzhou University), H. K. Harms(Sanford Burnham Prebys Medical Discovery Institute), Kurt Von Figura, K. Zimmer(Zentrum für Kinderheilkunde), Hudson H. Freeze(Discovery Institute)
Cited by 429
Related Papers
Essentials of Glycobiology
|Unknown|1999|2.5k
Plant Diversity and Productivity Experiments in European Grasslands
|Science|1999|2.1k
Symbol Nomenclature for Graphical Representations of Glycans
|Glycobiology|2015|1.1k
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells
|The Journal of Immunology|2008|728